Wallace Eli M. 4
4 · BridgeBio Oncology Therapeutics, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Wallace Eli M.
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-12-10−1,114,400→ 500,000 totalExercise: $12.44Exp: 2035-10-01→ Common Stock (1,114,400 underlying)
Footnotes (2)
- [F1]1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
- [F2]On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the "Rescinded Portion"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3.